BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
April 07 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company will present at the 20th Annual Needham Virtual
Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m. ET.
Links to a live audio webcast and replay of this
presentation may be accessed in the Investors section of BioCryst’s
website at http://www.biocryst.com.
About BioCryst
Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO™ (berotralstat) is approved in the United States and Japan
for the prevention of HAE attacks in adults and pediatric patients
12 years and older, and under regulatory review for approval in the
European Union and United Kingdom. BioCryst has several ongoing
development programs including BCX9930, an oral Factor D inhibitor
for the treatment of complement-mediated diseases, BCX9250, an
ALK-2 inhibitor for the treatment of fibrodysplasia ossificans
progressiva, and galidesivir, a potential treatment for Marburg
virus disease and Yellow Fever. RAPIVAB® (peramivir
injection), a viral neuraminidase inhibitor for the treatment of
influenza, has received regulatory approval in the U.S., Canada,
Australia, Japan, Taiwan and Korea. Post-marketing commitments for
RAPIVAB are ongoing. For more information, please visit the
company’s website at www.biocryst.com.
BCRXW
Contact:InvestorsJohn Bluth+1 919
859 7910jbluth@biocryst.com
MediaCatherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024